Configuring the PrEP user: framing pre-exposure prophylaxis in UK newsprint 2012–2016

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

HIV Pre-Exposure Prophylaxis (PrEP)—A Quantitative Ethics Appraisal

BACKGROUND There is now strong evidence that preventive oral antiretroviral therapy can moderately reduce likelihood of HIV infection. This concept is called HIV pre-exposure prophylaxis (PrEP). Premature closures of some previous PrEP clinical trials, secondary to ethical concerns, did not stop research. We aimed to appraise the extent of ethics considerations reporting in PrEP study documents...

Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP)

Interim statement on HIV pre-exposure prophylaxis (PrEP)

In recent years, a number of randomised clinical trials have been completed overseas wherein antiretrovirals in various formats were evaluated for the prevention of HIV infection.1,2 Subjects ranged from men who have sex with men (MSM), heterosexual men and women, to people who inject drugs. Major antiretrovirals evaluated included coformulated tenofovir disoproxil fumarate / emtricitabine (TDF...

Frame me if you must: PrEP framing and the impact on adherence to HIV Pre-exposure Prophylaxis